Stay updated on Grapiprant and Pembrolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Grapiprant and Pembrolizumab in NSCLC Clinical Trial page.

Latest updates to the Grapiprant and Pembrolizumab in NSCLC Clinical Trial page
- Check2 days agoNo Change Detected
- Check10 days agoChange DetectedThe page shows a revision update to v3.3.2, replacing the previous v3.3.1. No substantive study details, eligibility criteria, endpoints, or enrollment changes are observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check17 days agoChange DetectedRevision history updated from v3.2.0 to v3.3.1; no changes to study details or user-facing content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check24 days agoChange DetectedThe government funding lapse notice was removed from the page, which previously warned that information may not be up to date due to funding gaps. This is an administrative change that does not affect trial data or core content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check38 days agoChange DetectedNo substantive changes to the Study Details page were detected; all key sections and information remain as in the previous view.SummaryDifference0.5%

- Check67 days agoChange DetectedUpdated version to v3.2.0 and added a government-operating-status notice; removed the prior v3.1.0 tag.SummaryDifference4%

- Check74 days agoChange DetectedVersion bump from v3.0.2 to v3.1.0; no other content changes detected.SummaryDifference0.1%

Stay in the know with updates to Grapiprant and Pembrolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Grapiprant and Pembrolizumab in NSCLC Clinical Trial page.